IDH3A and central nervous system cancer: Numerous tumor‐specific genetic alterations such as typical isocitrate dehydrogenase (IDH) mutation and chromosome 1p/19q codeletion were routinely applied in diagnosis according to the 2021 World Health Organization (WHO) classification system, but whether these gene aberrations affect glioma progression remains debatable.3, 4